Study results presented today demonstrate that the oral, once-daily treatment regimen of glecaprevir/pibrentasvir resulted in 95 percent sustained virologic response rates 12 weeks post treatment in patients with HCV genotype 3. In the ENDURANCE-3 study, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, patients infected with HCV genotype 3 without cirrhosis and who had no previous treatment history were treated with the new regimen for eight or 12 weeks, which was well tolerated.